Metabolic Diseases Program
Metabolic syndrome, Diabetes, Fatty Liver Disease
Pre-clinicalActive
Key Facts
Indication
Metabolic syndrome, Diabetes, Fatty Liver Disease
Phase
Pre-clinical
Status
Active
Company
About Britecyte
Britecyte is a private, Seattle-based biotech founded in 2016, developing regenerative therapies based on its proprietary platform for non-immunogenic allogeneic adipose tissue. The company has two initial commercial products, Liposana and Lipoderma, for soft tissue restoration, and is exploring pipeline applications in metabolic diseases and osteoarthritis. Operating as a therapeutics company, Britecyte appears to be in an early commercial or pre-revenue stage, leveraging its scientific breakthrough to create ready-to-use adipose allografts that overcome the limitations of autologous tissue transfer.
View full company profile